Kasturi Banerjee

Kasturi Banerjee

Auto-generated profile, based on publicly available information

Kasturi Banerjee

Department of Medicine, Infectious Disease Division, Stony Brook University, Stony Brook, New York, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2019 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
RBRakesh Bhatia
Rakesh Bhatia
SGShailendra K. Gautam
Shailendra K. Gautam
ACAndrew Cannon
Andrew Cannon
CTChristopher Thompson
Christopher Thompson
BHBradley R. Hall
Bradley R. Hall
SBSurinder Kumar Batra
Surinder Kumar Batra

1 June 2019 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
MMMichael P. Motley
Michael P. Motley
KBKasturi Banerjee
Kasturi Banerjee
BFBettina C. Fries
Bettina C. Fries
Purpose of review: This review highlights recent developments in the development of monoclonal antibodies to treat bacterial disease, including preclinical advances and the status of current clinical trials. Recent findings: Monoclonal antibody (mAb) therapy is becoming increasingly promising in the infectious disease field. Though bacterial exotoxins continue to be a mainstay of mAb targets, searches for protein targets on the surface of bacteria have uncovered new mechanisms of antibody-mediated action against bacteria. Additionally, surveys of the polysaccharide serotype prevalence among antibiotic-resistant bacterial populations have yielded opportunities to leverage human selective pressures to our clinical advantage. Several mAb candidates are progressing through clinical development with great promise, especially those with structures altered to provide maximum benefit. Although other clinical trials have recently proved unsuccessful, these failures and lessons from immune profiling provide opportunities to understand how vulnerabilities of certain targets may change in different disease states. Summary: Despite the hurdles of identifying effective targets and understanding how mAbs provide protection within different infections, we show that the progress made in these fields is a positive indication of mAbs becoming more widely accepted as the future for treating bacterial infections.

1 March 2018 in Cancer Letters
Verified
Journal Article
Closed access
KBKasturi Banerjee
Kasturi Banerjee
SKSushil Kumar
Sushil Kumar
KRKathleen A. Ross
Kathleen A. Ross
SGShailendra Gautam
Shailendra Gautam
BPBrittany Poelaert
Brittany Poelaert
MJManeesh Jain
Maneesh Jain

1 May 2019 in Translational Research
Verified
Journal Article
Closed access
Maher AbdallaMaher Abdalla
Maher Abdalla
IAIman Ahmad
Iman Ahmad
SRSatyanarayana Rachagani
Satyanarayana Rachagani
KBKasturi Banerjee
Kasturi Banerjee
CTChristopher M. Thompson
Christopher M. Thompson
SKSushil Kumar
Sushil Kumar

1 March 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MMMUZAFAR AHMAD MACHA
MUZAFAR AHMAD MACHA
SKShiv Ram Krishn
Shiv Ram Krishn
RJRahat Jahan
Rahat Jahan
KBKasturi Banerjee
Kasturi Banerjee
SBSurinder K. Batra
Surinder K. Batra
MJManeesh Jain
Maneesh Jain

27 October 2020 in mBio
Verified
Journal Article
Closed access
PDF file
MMMichael P. Motley
Michael P. Motley
EDElizabeth Diago-Navarro
Elizabeth Diago-Navarro
KBKasturi Banerjee
Kasturi Banerjee
SISean Inzerillo
Sean Inzerillo
BFBettina Fries
Bettina Fries
Carbapenem-resistantKlebsiella pneumoniaeis an urgent public health threat that causes life-threatening infections in immunocompromised hosts. Its resistance to nearly all antibiotics necessitates novel strategies to treat it, including the use of monoclonal antibodies. Monoclonal antibodies are emerging as important adjuncts to traditional pharmaceuticals, and studying how they protect against specific bacteria such asKlebsiella pneumoniaeis crucial to their development as effective therapies. Antibody subclass is often overlooked but is a major factor in how an antibody interacts with other mediators of immunity. This paper is the first to examine how the subclass of anticapsular monoclonal antibodies can affect efficacy against CR-Kp. Additionally, this work sheds light on the viability of monoclonal antibody therapy in neutropenic patients, who are most vulnerable to CR-Kpinfection.